DHA (docosahexaenoic acid)

DIETARY_SUPPLEMENT3 trials

Sponsors

Alzheimer's Disease Cooperative Study (ADCS), University of Oxford, Ludwig-Maximilians - University of Munich

Conditions

Alzheimer's DiseaseBehaviourHealthyLearning

Phase 2

The DHA (Docosahexaenoic Acid) Oxford Learning and Behaviour (DOLAB) Study

CompletedNCT01066182

University of OxfordBehaviour, Learning

Start: 2009-01-31End: 2011-07-31Target: 360Updated: 2011-10-28

Phase 3

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

CompletedNCT00440050

Alzheimer's Disease Cooperative Study (ADCS)Alzheimer's Disease

Start: 2007-02-28End: 2009-05-31Updated: 2014-09-25

Unknown Phase

Cheek Cells - Non-invasive Fatty Acid Status Marker

CompletedNCT01192269

Ludwig-Maximilians - University of MunichHealthy

Start: 2010-08-31End: 2012-06-30Updated: 2012-07-03

Related Papers

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

2016-06-3052 citations

Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study).

2012-09-0698 citations

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

2010-11-01502 citations